Lupin Ltd


'Lupin Ltd' - 78 News Result(s)

  • These Two Stocks To Be Added Into Sensex

    These Two Stocks To Be Added Into Sensex

    Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.

  • Lupin Founder And Chairman Desh Bandhu Gupta Dies

    Lupin Founder And Chairman Desh Bandhu Gupta Dies

    Desh Bandhu Gupta, founder and chairman of pharmaceuticals company Lupin Ltd, died early morning on Monday in Mumbai.

  • Lupin Gets USFDA Nod To Market Cancer Drug

    Lupin Gets USFDA Nod To Market Cancer Drug

    Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in treatment of a form of cancer.

  • Lupin Launches Voriconazole Tablets For Treatment Of Fungal Infectinos

    Lupin Launches Voriconazole Tablets For Treatment Of Fungal Infectinos

    Homegrown pharma major Lupin Ltd on Monday announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infectinos in children.

  • Sensex Heads For Second Straight Fall; Lupin Drags

    Sensex Heads For Second Straight Fall; Lupin Drags

    Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.

  • Lupin Q1 Profit Jumps 55%, Gets Boost From Lower Tax Rate

    Lupin Q1 Profit Jumps 55%, Gets Boost From Lower Tax Rate

    Lupin Ltd, India's third largest drug maker, posted a 55 per cent rise in quarterly profit, but shares fell as some analysts noted the jump was driven in part by a lower tax rate.

  • Lupin To Buy 21 Branded Drugs From Japan's Shionogi

    Lupin To Buy 21 Branded Drugs From Japan's Shionogi

    Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.

  • Lupin Q2 Profit Lags Estimates on Fewer Drug Launches

    Lupin Q2 Profit Lags Estimates on Fewer Drug Launches

    Lupin Ltd, India's third largest drug maker by sales, hopes to win approvals for some key products in its largest market, the United States, by the end of this year, after fewer product launches pushed second-quarter profit below estimates.

  • Lupin Launches Hyperphosphatemia Treatment Capsules in US

    Lupin Launches Hyperphosphatemia Treatment Capsules in US

    Lupin has launched calcium acetate capsules, used in treating hyperphosphatemia in end stage renal failure, in the United States after receiving approval from the US Food and Drug Administration (FDA).

  • FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report

    FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report

    The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

  • Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

  • Lupin Acquires Russian Drug Firm Biocom

    Lupin Acquires Russian Drug Firm Biocom

    The company has acquired 100 per cent equity stake in ZAO Biocom in Russia subject to certain closing conditions, Lupin Ltd said in a statement without disclosing the financial details.

  • RBI Allows FIIs to Invest Upto 49% of Paid Up Capital in Lupin

    RBI Allows FIIs to Invest Upto 49% of Paid Up Capital in Lupin

    The Reserve Bank today said foreign institutional investors and registered foreign portfolios investors can now invest up to 49 per cent of the paid-up capital in Lupin Ltd under Portfolio Investment Scheme (PIS).

  • Lupin Gets USFDA Approval for Diarrhoea Drug

    Lupin Gets USFDA Approval for Diarrhoea Drug

    The company has received final approval for its Vancomycin Hydrochloride Capsules in strengths of 125 mg and 250 mg from the US Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals, Inc's Vancocin, Lupin Ltd said in a statement.

  • Court Order Restraining Drug Sale Disappointing: Cipla

    Court Order Restraining Drug Sale Disappointing: Cipla

    Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.

'Lupin Ltd' - 4 Video Result(s)

'Lupin Ltd' - 78 News Result(s)

  • These Two Stocks To Be Added Into Sensex

    These Two Stocks To Be Added Into Sensex

    Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.

  • Lupin Founder And Chairman Desh Bandhu Gupta Dies

    Lupin Founder And Chairman Desh Bandhu Gupta Dies

    Desh Bandhu Gupta, founder and chairman of pharmaceuticals company Lupin Ltd, died early morning on Monday in Mumbai.

  • Lupin Gets USFDA Nod To Market Cancer Drug

    Lupin Gets USFDA Nod To Market Cancer Drug

    Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in treatment of a form of cancer.

  • Lupin Launches Voriconazole Tablets For Treatment Of Fungal Infectinos

    Lupin Launches Voriconazole Tablets For Treatment Of Fungal Infectinos

    Homegrown pharma major Lupin Ltd on Monday announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infectinos in children.

  • Sensex Heads For Second Straight Fall; Lupin Drags

    Sensex Heads For Second Straight Fall; Lupin Drags

    Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.

  • Lupin Q1 Profit Jumps 55%, Gets Boost From Lower Tax Rate

    Lupin Q1 Profit Jumps 55%, Gets Boost From Lower Tax Rate

    Lupin Ltd, India's third largest drug maker, posted a 55 per cent rise in quarterly profit, but shares fell as some analysts noted the jump was driven in part by a lower tax rate.

  • Lupin To Buy 21 Branded Drugs From Japan's Shionogi

    Lupin To Buy 21 Branded Drugs From Japan's Shionogi

    Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.

  • Lupin Q2 Profit Lags Estimates on Fewer Drug Launches

    Lupin Q2 Profit Lags Estimates on Fewer Drug Launches

    Lupin Ltd, India's third largest drug maker by sales, hopes to win approvals for some key products in its largest market, the United States, by the end of this year, after fewer product launches pushed second-quarter profit below estimates.

  • Lupin Launches Hyperphosphatemia Treatment Capsules in US

    Lupin Launches Hyperphosphatemia Treatment Capsules in US

    Lupin has launched calcium acetate capsules, used in treating hyperphosphatemia in end stage renal failure, in the United States after receiving approval from the US Food and Drug Administration (FDA).

  • FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report

    FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report

    The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

  • Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

  • Lupin Acquires Russian Drug Firm Biocom

    Lupin Acquires Russian Drug Firm Biocom

    The company has acquired 100 per cent equity stake in ZAO Biocom in Russia subject to certain closing conditions, Lupin Ltd said in a statement without disclosing the financial details.

  • RBI Allows FIIs to Invest Upto 49% of Paid Up Capital in Lupin

    RBI Allows FIIs to Invest Upto 49% of Paid Up Capital in Lupin

    The Reserve Bank today said foreign institutional investors and registered foreign portfolios investors can now invest up to 49 per cent of the paid-up capital in Lupin Ltd under Portfolio Investment Scheme (PIS).

  • Lupin Gets USFDA Approval for Diarrhoea Drug

    Lupin Gets USFDA Approval for Diarrhoea Drug

    The company has received final approval for its Vancomycin Hydrochloride Capsules in strengths of 125 mg and 250 mg from the US Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals, Inc's Vancocin, Lupin Ltd said in a statement.

  • Court Order Restraining Drug Sale Disappointing: Cipla

    Court Order Restraining Drug Sale Disappointing: Cipla

    Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.

Your search did not match any documents
A few suggestions
  • Make sure all words are spelled correctly
  • Try different keywords
  • Try more general keywords
Check the NDTV Archives:https://archives.ndtv.com

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com